Table 2.
Clinical and treatment characteristics
| Total (N = 41) | |
|---|---|
| Time since schizophrenia diagnosis (years) | |
| n | 41 |
| Mean (SD) | 11.8 (12.26) |
| Median | 6.5 |
| Q1; Q3 | 0.8; 20.4 |
| Range | 0; 39 |
| Reason to initiate LUR treatment, n (%) | |
| First choice treatment | 5 (12.20) |
| Previous drugs adherence problems | 12 (29.27) |
| Previous drugs lack of efficacy | 15 (36.59) |
| Previous drugs tolerability problems | 6 (14.63) |
| Other | 3 (7.32) |
| Health setting at LUR initiation, n (%) | |
| Hospital | 22 (53.66) |
| Outpatient visit | 19 (46.34) |
| CGI-S measurement at lurasidone initiation, n (%) | |
| Borderline mentally ill | 2 (4.88) |
| Mildly ill | 1 (2.44) |
| Moderately ill | 8 (19.51) |
| Markedly ill | 7 (17.07) |
| Severely ill | 12 (29.27) |
| Missing | 11 (26.83) |
Index date is defined as LUR start date. Time from diagnosis is defined as: index date—date of diagnosis + 1. Percentages were computed on the eligible population
CGI-S Clinical Global Impression—Severity scale, LUR lurasidone, Q1 first quartile, Q3 third quartile, SD standard deviation